NV-NTT
The city of Las Vegas and NTT Corporation (NTT) today announced the Accelerate Smart project has expanded to include two new locations – the city’s Community Healing Garden and a portion of Las Vegas Boulevard at South Main Street and East St. Louis Avenue. As part of the partnership, NTT and the city plan to further expand the smart cities project to Bob Baskin Park, Rotary Park, Stupak Park and Ethel Pearson Park this summer before adding six additional parks by the end of 2020.
Following the success of the initial pilot , which has improved traffic congestion and wrong way driving, NTT will expand the project to provide real-time alerts of safety conditions and maintenance issues to improve public safety and provide a better experience for citizens and visitors. The city’s Smart Park Initiative is designed to increase public safety, while providing awareness of activity to generate usage and operations benchmarks that allow leadership to make more informed decisions.
In total, high-definition optical and audio sensors will now be deployed at 14 locations across the city, which enable an automated system to notify law enforcement and maintenance personnel of safety hazards, such as large crowds, gunshots, breaking glass and vandalism.
“Cities that learn, understand and invest in technology will be the cities of the future, and Las Vegas is at the forefront of innovation,” said Michael Sherwood, Director of Innovation and Technology, city of Las Vegas. “Our Smart Cities pilot has been such a success that we are excited to expand the program to several new locations in the heart of our city, which will continue to improve the lives of our residents and visitors.”
The initial proof of concept provided information to city personnel to increase situational awareness and provide a foundation for traffic management. With the expansion of the smart cities project, Las Vegas will leverage a dashboard to access and view sensors, data streams and analytics. The timely alerts and predictions enable the city to monitor and review events and allow them to dispatch safety and maintenance personnel in a timely manner.
The NTT Accelerate Smart data platform is a secure, distributed platform that captures data via sensors and micro data centers in the designated areas through video and sound, while also integrating historical data sources such as crime, weather and social media. By leveraging cognitive analytics, including machine learning technologies, the system learns normal patterns and can detect and alert authorities of patterns that appear abnormal.
“As we accelerate our smart cities project in Las Vegas, it demonstrates how a more connected society directly benefits citizens,” said Bill Baver, Go to Market Leader, Smart World Team, NTT. “Cities like Las Vegas are capitalizing on successful pilots and beginning to imagine the benefits these technologies can have for their residents and visitors. However, smart is not confined to city limits, as it also extends to stadiums, shopping malls and manufacturing facilities by leveraging similar concepts that have been proven successful in Las Vegas.”
The Accelerate Smart solution deployed in Las Vegas is built on NTT’s innovative Cognitive Foundation™ architecture, which enables remote creation, management and operation of information and communications technology resources, from devices and networks to the cloud. It also incorporates hyperconverged infrastructure and IoT gateways, as well as virtualization software hosting predictive analytics applications.
The partnership with NTT is part of the city of Las Vegas’ charter in becoming a smart city to provide safe, reliable and efficient civic technology that stimulates economic growth. To learn more about the Smart Cities initiative in Las Vegas, visit NTT’s website and watch the case study on YouTube .
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005261/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom